APLS
Apellis Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.19B
P/E Ratio
225.72
EPS
$0.18
Beta
-0.20
52W High
$40.69
52W Low
$16.10
50-Day MA
$22.25
200-Day MA
$22.87
Dividend Yield
—
Profit Margin
2.23%
Forward P/E
46.30
PEG Ratio
—
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $1.00B |
| Gross Profit (TTM) | $605.69M |
| EBITDA | $56.98M |
| Operating Margin | -25.60% |
| Return on Equity | 7.48% |
| Return on Assets | 3.53% |
| Revenue/Share (TTM) | $7.96 |
| Book Value | $2.92 |
| Price-to-Book | 13.96 |
| Price-to-Sales (TTM) | 5.17 |
| EV/Revenue | 5.15 |
| EV/EBITDA | 73.92 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -5.90% |
| Shares Outstanding | $127.84M |
| Float | $83.25M |
| % Insiders | 13.74% |
| % Institutions | 100.68% |
Analyst Ratings
Consensus ($38.60 target)
2
Strong Buy5
Buy13
HoldData last updated: 4/7/2026